Prothena Corp Public (PRTA) Total Current Liabilities (2012 - 2026)
Prothena Corp Public's (PRTA) quarterly Total Current Liabilities came in at $32.5 million in Q1 2026, down 32.9% year-on-year from $48.5 million in Q1 2025, and down 20.39% quarter-over-quarter from $40.8 million in Q4 2025.
Prothena Corp Public (PRTA) Total Current Liabilities (2012 - 2026) Analysis & Trends
Prothena Corp Public's Total Current Liabilities history runs 15 years deep, the most recent figure standing at $32.5 million for Q1 2026.
- On a quarterly basis, Total Current Liabilities fell 32.9% year-over-year to $32.5 million in Q1 2026; TTM through Mar 2026 was $32.5 million, a 32.9% decrease from a year earlier, with the FY2025 full-year figure at $40.8 million, down 15.79% from the prior year.
- Total Current Liabilities slipped to $32.5 million in Q1 2026 per PRTA's latest filing, from $40.8 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $71.6 million in Q2 2023 and bottomed at $32.5 million in Q1 2026.
- The 5-year median for Total Current Liabilities is $48.5 million (2024), against an average of $49.1 million.
- Across the five-year window, Total Current Liabilities surged 78.44% in 2023 and sank 34.68% in 2024, its largest moves.
- Year by year, Total Current Liabilities stood at $50.1 million in 2022, then increased by 13.45% to $56.9 million in 2023, then fell by 14.75% to $48.5 million in 2024, then fell by 15.79% to $40.8 million in 2025, then retreated by 20.39% to $32.5 million in 2026.
- Per Business Quant, the three latest PRTA Total Current Liabilities figures stand at $32.5 million (Q1 2026), $40.8 million (Q4 2025), and $51.4 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 56.01 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | 66.94 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 13.42 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 1.81 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 3.88 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 5.11 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 289.60 Mn |
| 10 | Prothena Corp Public | 467.80 Mn | 138.33 Mn | - | 32.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 32.52 Mn |
| Dec 31, 2025 | 40.84 Mn |
| Sep 30, 2025 | 51.44 Mn |
| Jun 30, 2025 | 67.81 Mn |
| Mar 31, 2025 | 48.46 Mn |
| Dec 31, 2024 | 48.50 Mn |
| Sep 30, 2024 | 46.42 Mn |
| Jun 30, 2024 | 46.74 Mn |
| Mar 31, 2024 | 43.27 Mn |
| Dec 31, 2023 | 56.89 Mn |
| Sep 30, 2023 | 53.37 Mn |
| Jun 30, 2023 | 71.57 Mn |
| Mar 31, 2023 | 48.88 Mn |
| Dec 31, 2022 | 50.15 Mn |
| Sep 30, 2022 | 50.60 Mn |
| Jun 30, 2022 | 40.11 Mn |
| Mar 31, 2022 | 36.50 Mn |
| Dec 31, 2021 | 33.45 Mn |
| Sep 30, 2021 | 29.20 Mn |
| Jun 30, 2021 | 52.90 Mn |